Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
The use of adjuvant and early salvage androgen deprivation in high-risk prostate cancer patients
EF 2017-18
Résumé
Prostate cancer is the most commonly diagnosed cancer among Canadian men. Radical prostatectomy, the surgical removal of the prostate, is chosen as the primary treatment in nearly 50% of patients with clinically localized disease. While many patients undergoing prostatectomy will be cured with surgery alone, a proportion of patients will experience cancer recurrence. For these high-risk radical prostatectomy patients, adjuvant or early salvage therapy may be crucial to achieve cure. Pelvic radiation is an established option that achieves cure in many patients, however it exposes patients to considerable risk of short-term and long-term morbidity. Certainly, cancer cure is of utmost importance to patients and many patients also would like to avoid the long-term effects of pelvic radiation following surgery.Androgen deprivation therapy (ADT) is a first-line hormonal treatment for patients with metastatic disease and is proven to improve survival when used in combination with primary pelvic radiation. However, no clinical trials have evaluated the effect of adjuvant or early salvage ADT monotherapy. Retrospective studies of adjuvant ADT following prostatectomy are limited but suggest ADT may be beneficial. This project aims to describe a cohort of patients treated with adjuvant or early salvage ADT, systematically review the literature addressing adjuvant and early salvage ADT, and survey clinicians and patients about use and perceptions of adjuvant ADT. These initiatives will provide a better understanding of the benefits and risks of adjuvant hormonal therapy, and will determine the feasibility of a future clinical trial that would have a profound impact on a large number of men with prostate cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386514
Name
Nayak Ameeta L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The use of adjuvant and early salvage androgen deprivation in high-risk prostate cancer patients
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjuvant Therapy; Androgen Deprivation Therapy; Cancer Recurrence; High-Risk Prostate Cancer; Radical Prostatectomy; Salvage Therapy
Abstract
Prostate cancer is the most commonly diagnosed cancer among Canadian men. Radical prostatectomy, the surgical removal of the prostate, is chosen as the primary treatment in nearly 50% of patients with clinically localized disease. While many patients undergoing prostatectomy will be cured with surgery alone, a proportion of patients will experience cancer recurrence. For these high-risk radical prostatectomy patients, adjuvant or early salvage therapy may be crucial to achieve cure. Pelvic radiation is an established option that achieves cure in many patients, however it exposes patients to considerable risk of short-term and long-term morbidity. Certainly, cancer cure is of utmost importance to patients and many patients also would like to avoid the long-term effects of pelvic radiation following surgery.Androgen deprivation therapy (ADT) is a first-line hormonal treatment for patients with metastatic disease and is proven to improve survival when used in combination with primary pelvic radiation. However, no clinical trials have evaluated the effect of adjuvant or early salvage ADT monotherapy. Retrospective studies of adjuvant ADT following prostatectomy are limited but suggest ADT may be beneficial. This project aims to describe a cohort of patients treated with adjuvant or early salvage ADT, systematically review the literature addressing adjuvant and early salvage ADT, and survey clinicians and patients about use and perceptions of adjuvant ADT. These initiatives will provide a better understanding of the benefits and risks of adjuvant hormonal therapy, and will determine the feasibility of a future clinical trial that would have a profound impact on a large number of men with prostate cancer.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nayak, Ameeta L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~